Adam Kern

Prof. Adam Kern

University of Warmia and Mazury in Olsztyn, Poland
+2
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2016 in EuroIntervention
Verified
Journal Article
Closed access
RGRobert Julian Gil
Robert Julian Gil
JBJacek Bil
Jacek Bil
MGMaik Grundeken
Maik Grundeken
Adam KernAdam Kern
Adam Kern
LGLuis Iñigo Garcia
Luis Iñigo Garcia
PSPatrick Serruys
Patrick Serruys
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

1 July 2012 in EuroIntervention
Verified
Journal Article
Closed access
RGRobert Julian Gil
Robert Julian Gil
DVDobrin Vasilev
Dobrin Vasilev
AMAleksandra Michalek
Aleksandra Michalek
Adam KernAdam Kern
Adam Kern
RFRadoslaw Formuszewicz
Radoslaw Formuszewicz
ALAndrzej Lekston
Andrzej Lekston
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

1 May 2015 in Canadian Journal of Cardiology
Verified
Journal Article
Closed access
RGRobert Julian Gil
Robert Julian Gil
JBJacek Bil
Jacek Bil
VDVladimír Džavík
Vladimír Džavík
DVDobrin Vasilev
Dobrin Vasilev
Adam KernAdam Kern
Adam Kern
SDSławomir Dobrzycki
Sławomir Dobrzycki

27 June 2017 in European Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
Adam KernAdam Kern
Adam Kern
RGRobert Julian Gil
Robert Julian Gil
KBKrystian Bojko
Krystian Bojko
ESEwa Sienkiewicz
Ewa Sienkiewicz
BJBeata Januszko-Giergielewicz
Beata Januszko-Giergielewicz
JBJacek Bil
Jacek Bil

1 November 2016 in EuroIntervention
Verified
Journal Article
Closed access
RGRobert Julian Gil
Robert Julian Gil
JBJacek Bil
Jacek Bil
MGMaik Grundeken
Maik Grundeken
LGLuis Iñigo Garcia
Luis Iñigo Garcia
DVDobrin Vasilev
Dobrin Vasilev
PSPatrick Serruys
Patrick Serruys
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

14 November 2015 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
JBJacek Bil
Jacek Bil
RGRobert Julian Gil
Robert Julian Gil
Adam KernAdam Kern
Adam Kern
TPTomasz Pawłowski
Tomasz Pawłowski
PSPiotr Seweryniak
Piotr Seweryniak
ZŚZbigniew Śliwiński
Zbigniew Śliwiński
The aim of this study was to assess the safety and the efficacy of the novel sirolimus-eluting Prolim® stent with a biodegradable polymer in the all-comers population. We prospectively enrolled all patients with stable coronary artery disease or acute coronary syndrome treated with Prolim® stent between January and December 2013 in two interventional cardiology centers in Poland. Angiographic control was planned at 12 months, in which 15 % of patients (randomly chosen) underwent optical coherence tomography imaging. The primary end-point was the cumulative rate of cardiac death, myocardial infarction, and target lesion revascularization at 12 months. There were 204 patients enrolled, in whom 238 Prolim® stents were deployed (1.17 stent per patient). The mean age was 68 ± 10 years and 32.8 % were females. The examined stent was implanted in 5.9 % in STEMI patients, in 21.6 % - in NSTE-ACS and in 72.5 % - in patients with stable coronary artery disease. The Prolim® stent was most frequently implanted in right coronary artery (38.2 %) followed by left anterior descending artery (34.0 %). The cumulative major adverse cardiovascular events rate at 12 months was 6.9 %, and the clinically-driven target lesion revascularization rate – 5.4 %. At 12 months in quantitative coronary angiography the late lumen loss was 0.21 ± 0.18 mm, and in optical coherence tomography the mean neointima burden was 24.6 ± 8.6 %. Sirolimus-eluting Prolim® stent with a biodegradable polymer is a feasible device with a very good safety profile and long-term clinical effectiveness. ClinicalTrials.gov NCT02545985 .